The glucose monitoring device market in the Middle East and Africa is likely to account for USD 0.27 billion in 2027, growing at a CAGR of 6.08% from USD 0.20 billion in 2027.
The glucose level in the blood can be detected by using these glucose monitoring devices, and these are of several kinds, which include glucose meter, testing strips, and lancets. By using a single glucose meter and different strips, we can self-test the sugar level.
The continuous glucose monitoring results help patients regulate their food intake, exercise, and medications. The device contains sensors for checking the glucose levels from the interstitial fluid. The sensor has a time span where it can be used in one place and then replaced. This device monitors the glucose levels over time, allowing the patients to identify low and high sugar levels, which are more dangerous. For the self-monitoring devices, people have to test, and it monitors the level at that particular time and not before that.
It offers the services of monitoring glucose levels in our blood as it tests quantitatively. These devices can be handled easily as they are portable so convenient to carry. The devices allow the test to be performed by the patient as per their convenience at their home, making them popular.
The healthcare expenditure is increasing, which is the direct cause of the increase in the growth of self-monitoring blood glucose devices. The increasing prevalence of diabetes cases is due to an unhealthy lifestyle, poor diet, excess alcohol consumption, and lack of physical activity.
However, this market faces certain losses due to some manufacturing defect or error in results.
This research report on the Middle East and Africa glucose monitoring device market has been segmented and sub-segmented into the following categories:
By Device Type:
Companies playing a dominating role in the MEA Monitoring Device Market profiled in this report are Roche Diagnostics, LifeScan, Bayer Health care, Abbott Diabetes care Inc., AgaMatrix Inc., Arkray Inc., Medtronic, DexCom Inc., Nova Biomedical Corporation, and Terumo Europe NV.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org